What is HC Wainwright's Forecast for GALT Q3 Earnings?

Key Points

• HC Wainwright has increased its Q3 2025 EPS estimates for Galectin Therapeutics, now projecting earnings of ($0.11) per share, up from the previous estimate of ($0.18).
• Galectin Therapeutics reported Q2 earnings of ($0.12) EPS, surpassing consensus estimates of ($0.16) by $0.04.
• Institutional investors have been actively buying shares, with notable increases by firms such as Jane Street Group LLC and Vivaldi Capital Management LP during the second quarter.

Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) - Research analysts at HC Wainwright boosted their Q3 2025 earnings estimates for shares of Galectin Therapeutics in a report released on Thursday, August 14th. HC Wainwright analyst M. Keller now anticipates that the company will post earnings of ($0.11) per share for the quarter, up from their prior estimate of ($0.18). HC Wainwright has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for Galectin Therapeutics' current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics' Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.44) EPS and FY2027 earnings at ($0.49) EPS.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.04.

Separately, Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, June 21st. One analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $6.00.

Galectin Therapeutics Trading Up 5.7%

Galectin Therapeutics stock traded up $0.22 on Monday, hitting $4.10. 253,670 shares of the stock traded hands, compared to its average volume of 286,838. The firm has a market cap of $262.65 million, a P/E ratio of -6.41 and a beta of 0.82. The business's fifty day simple moving average is $3.00 and its 200 day simple moving average is $1.96. Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.41.

Institutional Investors Weigh In On Galectin Therapeutics

Institutional investors have recently modified their holdings of the stock. Wealth Enhancement Advisory Services LLC grew its stake in shares of Galectin Therapeutics by 46.8% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 51,510 shares of the company's stock worth $66,000 after acquiring an additional 16,412 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Galectin Therapeutics in the first quarter worth $287,000. Vivaldi Capital Management LP grew its stake in shares of Galectin Therapeutics by 89.9% in the fourth quarter. Vivaldi Capital Management LP now owns 45,628 shares of the company's stock worth $56,000 after acquiring an additional 21,596 shares during the last quarter. Barclays PLC grew its stake in shares of Galectin Therapeutics by 91.1% in the fourth quarter. Barclays PLC now owns 54,634 shares of the company's stock worth $71,000 after acquiring an additional 26,047 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Galectin Therapeutics by 4.3% in the fourth quarter. Northern Trust Corp now owns 244,274 shares of the company's stock worth $315,000 after acquiring an additional 9,994 shares during the last quarter. 11.68% of the stock is owned by hedge funds and other institutional investors.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.